294 related articles for article (PubMed ID: 19380217)
1. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Richards TM; Plowman PN; Reznek R; Ball SA
Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
[No Abstract] [Full Text] [Related]
2. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
Verzoni E; Lanocita R; Procopio G
Clin Genitourin Cancer; 2012 Jun; 10(2):130-3. PubMed ID: 22226825
[No Abstract] [Full Text] [Related]
3. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
[TBL] [Abstract][Full Text] [Related]
4. Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
Di Lorenzo G; Autorino R
J Urol; 2010 Feb; 183(2):824-5; author reply 825. PubMed ID: 20022057
[No Abstract] [Full Text] [Related]
5. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
Ravaud A; Digue L; Trufflandier N; Smith D
Ann Oncol; 2010 Feb; 21(2):431-432. PubMed ID: 19945958
[No Abstract] [Full Text] [Related]
6. [Targeted therapy - point blank or single shot].
Rübben H
Urologe A; 2008 Oct; 47(10):1297. PubMed ID: 18682912
[No Abstract] [Full Text] [Related]
7. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
8. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
Herrmann E; Marschner N; Grimm MO; Ohlmann CH; Hutzschenreuter U; Overkamp F; Groschek M; Blumenstengel K; Pühse G; Steiner T
World J Urol; 2011 Jun; 29(3):361-6. PubMed ID: 21461939
[TBL] [Abstract][Full Text] [Related]
9. Sequential sorafenib and sunitinib for renal cell carcinoma.
Sablin MP; Negrier S; Ravaud A; Oudard S; Balleyguier C; Gautier J; Celier C; Medioni J; Escudier B
J Urol; 2009 Jul; 182(1):29-34; discussion 34. PubMed ID: 19447417
[TBL] [Abstract][Full Text] [Related]
10. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Yuasa T; Urakami S; Yamamoto S; Yonese J; Nakano K; Kodaira M; Takahashi S; Hatake K; Inamura K; Ishikwa Y; Fukui I
Urology; 2011 Apr; 77(4):831-5. PubMed ID: 21316083
[TBL] [Abstract][Full Text] [Related]
11. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
Dudek AZ; Zolnierek J; Dham A; Lindgren BR; Szczylik C
Cancer; 2009 Jan; 115(1):61-7. PubMed ID: 19051290
[TBL] [Abstract][Full Text] [Related]
12. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Porta C; Procopio G; Cartenì G; Sabbatini R; Bearz A; Chiappino I; Ruggeri EM; Re GL; Ricotta R; Zustovich F; Landi L; Calcagno A; Imarisio I; Verzoni E; Rizzo M; Paglino C; Guadalupi V; Bajetta E
BJU Int; 2011 Oct; 108(8 Pt 2):E250-7. PubMed ID: 21599821
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
[TBL] [Abstract][Full Text] [Related]
14. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
[TBL] [Abstract][Full Text] [Related]
15. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
Miller K; Bergmann L; Albers P; Jäger E; Jakse G; Geschwend JE; Marschner N
Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172
[TBL] [Abstract][Full Text] [Related]
16. Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Bamias A
Eur Urol; 2009 Jun; 55(6):1439. PubMed ID: 18950935
[No Abstract] [Full Text] [Related]
17. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
18. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
Masini C; Sabbatini R; Porta C; Procopio G; Di Lorenzo G; Onofri A; Buti S; Iacovelli R; Invernizzi R; Moscetti L; Aste MG; Pagano M; Grosso F; Lucia Manenti A; Ortega C; Cosmai L; Del Giovane C; Conte PF
BJU Int; 2012 Sep; 110(5):692-8. PubMed ID: 22364110
[TBL] [Abstract][Full Text] [Related]
19. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]